Tight control of proteinuria in newly diagnosed lupus nephritis The last 3 years have been exciting times in the field of lupus nephritis (LN) with two new licensed therapies, belimumab (BAFF-inhibitor) and voclosporin (calcineurin-inhibitor). https://t.co/InkX6I7qUm https://t.co/U1M1DtF8Id

Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE https://t.co/ZktIKo1eVl https://t.co/dtxVXZFXpk

Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. https://t.co/4dNRsNP7IJ https://t.co/KOjJudfdcw

Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors. https://t.co/78whpnLkhd https://t.co/yxwSGR3hTV

3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/VsRDg5Utik https://t.co/AMqHUveJ6e

Top 10 Pharma Revenues 2021: 1 J&J $93.77 billion (USD) 2 Pfizer $81.29 B 3 Roche $68.7 B 4 AbbVie S$56.2 B 5 Novartis $51.63 B 6 Merck $48.7 B 7 BMS $46.4 B 8 GSK $43.57 B 9. Sanofi $44.67 B 10. AstraZeneca $37.47 B https://t.co/UBVjw2xBUF https://t.co/3MhhQzdyxG

Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/HsVWlebfL2 https://t.co/dixoeHNkFQ

The Top 10 Research Priorities in Psoriatic Arthritis A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA). https://t.co/qvcB3OkJUS https://t.co/EuD3qhOb5a

Why treatment of pre-RA isn't ready for prime time The ACR Great Debate was on "To treat or not to treat in pre-RA?" and it was stressed that autoimmunity may start well before clinical symptoms occur. https://t.co/TcKRc0w4i9 https://t.co/OkmlxTiAbm

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes) https://t.co/f7o8UARKNl https://t.co/ryVmD86UoI